Wired
US · 2 hrs ago
✦ 72◉ Centre
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
72Quality
0Ratings
0Comments
AI Analysis
Quality 72/100
Partisan intensity 35/100
ObjectivePartisan
◉ Centre ✓ Fair headline
A longevity startup has administered ER-100, a technology claimed to reverse cellular aging, to a human patient for the first time in an attempt to treat age-related vision loss.
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
It will be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human.
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!